

**Fiscal Year 2009 (FY09) Amyotrophic Lateral Sclerosis Research Program (ALSRP)
Reference Table of Award Mechanism and Submission Requirements**

| Award Mechanism | Eligibility | Key Mechanism Elements | Funding | Submission Deadlines |
|---|--|--|---|--|
| <p>Therapeutic Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • Application Instructions and General Information <p>Grants.gov Funding Opportunity Number: W81XWH-09-ALSRP-TDA</p> | <p align="center">Independent investigators at all academic levels</p> | <ul style="list-style-type: none"> • Supports preclinical development of therapeutics for ALS • Specific focus areas include development of high-throughput screens up to the submission of IND for later clinical trials • Preliminary data are required, relevant to the phase of preclinical development • Clinical trials are <u>not</u> allowed under this mechanism. | <ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$1,500,000 in direct costs. • More cost-effective studies not requesting the full funding amount are encouraged. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. | <p>Pre-Application (Pre-proposal): July 15, 2009 5:00 pm Eastern Time</p> <p>Pre-proposal is required; Application submission is by invitation only</p> <p>Application: October 15, 2009 11:59 pm Eastern Time</p> |